➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
McKinsey
Dow
McKesson
AstraZeneca

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Faldaprevir


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Faldaprevir?

Faldaprevir is an investigational drug.

There have been 23 clinical trials for Faldaprevir. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2011.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis C, Chronic. The leading clinical trial sponsors are Boehringer Ingelheim, Trek Therapeutics, PBC, and Hospital Regional de Malaga.

There are twenty-three US patents protecting this investigational drug and three hundred and forty-five international patents.

Recent Clinical Trials for Faldaprevir
TitleSponsorPhase
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus InfectionTrek Therapeutics, PBCPhase 2
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionTrek Therapeutics, PBCPhase 2
A Study to Investigate the Phototoxic Potential of FaldaprevirBoehringer IngelheimPhase 1

See all Faldaprevir clinical trials

Clinical Trial Summary for Faldaprevir

Top disease conditions for Faldaprevir
Top clinical trial sponsors for Faldaprevir

See all Faldaprevir clinical trials

US Patents for Faldaprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Faldaprevir   Start Trial Hepatitis C inhibitor compounds Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Faldaprevir   Start Trial Hepatitis C inhibitor compounds Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Faldaprevir   Start Trial Crystalline forms of a potent HCV inhibitor Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Faldaprevir   Start Trial Crystalline forms of a potent HCV inhibitor Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Faldaprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Faldaprevir Austria 378334 2023-05-21   Start Trial
Faldaprevir Australia 2004240704 2023-05-21   Start Trial
Faldaprevir Brazil PI0410456 2023-05-21   Start Trial
Faldaprevir Canada 2522577 2023-05-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Johnson and Johnson
Boehringer Ingelheim
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.